Silexion Therapeutics Corp
For the period ended Dec 31, 2024. Filed Mar 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 18, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Silexion Therapeutics Corp | |
|---|---|
| By: | /s/ Ilan Hadar |
| Name: | Ilan Hadar |
| Title: | Chairman of the Board and Chief Executive Officer |
| Date: | March 18, 2025 |
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Name | Position | Date |
|---|---|---|
| /s/ Ilan Hadar | Chairman of the Board and Chief Executive Officer | March 18, 2025 |
| Ilan Hadar | (Principal Executive Officer) | |
| /s/ Mirirt Horenshtein Hadar | Chief Financial Officer | March 18, 2025 |
| Mirirt Horenshtein Hadar | (Principal Financial and Accounting Officer) | |
| /s/ Ruth Alon | Director | March 18, 2025 |
| Ruth Alon | ||
| /s/ Dror Abramov | Director | March 18, 2025 |
| Dror Abramov | ||
| /s/ Ilan Levin | Director | March 18, 2025 |
| Ilan Levin | ||
| /s/ Avner Lushi | Director | March 18, 2025 |
| Avner Lushi | ||
| /s/ Shlomo Noy | Director | March 18, 2025 |
| Shlomo Noy | ||
| /s/ Amnon Peled | Director | March 18, 2025 |
| Amnon Peled | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.